The contraindications for Venetoclax involve specific drug interactions and genetic metabolic abnormalities, and medication for special populations needs to be adjusted based on pregnancy status, liver and kidney function, and other factors. The following is a detailed explanation of contraindications and medication for special populations.

1. Contraindications

(1) Combination therapy contraindications: Do not use in combination with potent CYP3A4 inhibitors, as it may lead to abnormally high blood concentrations of Vinaclotide.

(2) Genetic metabolic abnormalities: Patients with glucose-6-phosphate dehydrogenase deficiency should avoid using it, which may induce hemolytic anemia.

2. Medication for special populations

(1) Pregnancy period: Animal studies have shown embryotoxicity, and pregnant women should avoid using it. Before treatment, it is necessary to confirm the pregnancy status, and effective contraception should be used during the medication period and within 30 days after the last dose.

(2) Breastfeeding period: Medications may be secreted with breast milk. Breastfeeding should be stopped during treatment and within one week after discontinuation of medication.

(3) Children: Safety and efficacy have not been established for patients under 18 years old, and its use is not recommended.

(4) Elderly: Patients aged 65 or older do not need to adjust their dosage, but need to strengthen monitoring of adverse reactions.

(5) Liver dysfunction: mild to moderate damage does not require dose adjustment; Patients with severe damage (Child Pugh C) need to reduce their dosage by 50%.

(6) Renal insufficiency: mild to moderate damage does not require dose adjustment; There is insufficient data for patients with severe damage (eGFR<30mL/min), and caution is recommended when using it.